{"id":"ckd-351","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal dryness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CKD-351 functions as a SERD by binding to the estrogen receptor with high affinity and promoting its proteasomal degradation, thereby eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism differs from selective estrogen receptor modulators (SERMs) by achieving complete receptor elimination rather than partial antagonism. The drug is designed to overcome resistance mechanisms that develop with conventional endocrine therapies in estrogen receptor-positive breast cancer.","oneSentence":"CKD-351 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:11.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT04448223","phase":"PHASE2","title":"A Clinical Study to Evaluate the Efficacy and Safety of CKD-351","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-06-11","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":100},{"nctId":"NCT03762369","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy and Safety of CKD-351","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-12-07","conditions":"Primary Open-angle Glaucoma, Ocular Hypertension","enrollment":384},{"nctId":"NCT03067415","phase":"PHASE2","title":"Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-03-30","conditions":"Glaucoma, Primary Open Angle, Ocular Hypertension","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Latanoprost+D930"],"phase":"phase_3","status":"active","brandName":"CKD-351","genericName":"CKD-351","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CKD-351 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers. Used for Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}